Letters to the Editor
Thyroid Nodules and Survivors of Hodgkin's Disease
Am Fam Physician. 2003 Sep 15;68(6):1016-1019.
to the editor: The article, “Thyroid Nodules,”1 was well written and concise. However, the list of “red flags” for thyroid cancer listed in Table 2 needs to be expanded to include an additional risk group. The item, “history of radiation to the head or neck” also should include chest or mantle radiation. At particular risk for this radiation exposure are survivors of Hodgkin's disease.
Hodgkin's disease is the most common cancer diagnosed in persons 15 to 19 years of age, and is the third most common cancer for all pediatric ages, zero to 19 years.2 Radiation therapy involving the chest or mantle area has been used in the treatment of Hodgkin's disease for decades. Standardized anatomic treatment fields, combined with the establishment of a curative dose range, produced the first cures in patients with Hodgkin's disease. Radiation treatment regimens used through the 1980s primarily prescribed doses of 35 to 44 Gy to extended fields for localized disease (stage I or IIA).
Concerns about growth impairment led to clinical trials designed to specifically address the needs of children with Hodgkin's disease. These protocols evaluated lower radiation doses (15 to 25.5 Gy) to reduced treatment fields combined with multi-agent chemotherapy. Many reports implicating radiation as a causative factor for excess cardiovascular disease and subsequent malignancy risk in long-term survivors of childhood Hodgkin's disease motivated further therapeutic refinements in the 1990s. The use of standard-dose, extended-field radiation in mature adolescents with localized Hodgkin's disease has been abandoned at most centers, because this treatment approach predisposes patients to a greater risk of cardiovascular disease and secondary solid tumor carcinogenesis. Contemporary risk-adapted treatment protocols have focused on further limiting radiation exposure of uninvolved tissues, especially the breast, and identifying patients for whom the addition of radiation optimizes disease-free survival.
The Childhood Cancer Survivor Study,3 a 26-institution retrospective cohort study following almost 14,000 long-term survivors of childhood cancer diagnosed between 1970 and 1986, highlighted the risk of thyroid cancer following treatment for Hodgkin's disease. A cohort of 1,791 long-term survivors of Hodgkin's disease, diagnosed before the age of 21 years, were analyzed. The median age at diagnosis was 14 years and was 30 years at follow-up. From this relatively young population, 20 patients were diagnosed with thyroid cancer. Fifteen had received previous radiation therapy for their Hodgkin's disease, one had not, and treatment records were unavailable for the remaining four. The relative risk for thyroid cancer was 18.3 for all Hodgkin's survivors. Since that report, the number of new cases of thyroid cancer in the study's cohort has increased. A nested case-control study of 72 survivors with thyroid cancer as a second malignancy, including 30 Hodgkin's survivors, is underway to determine the attributable excess risk related to radiation.
As risk-adapted therapy for Hodgkin's disease continues to evolve, it is important that clinicians recognize the significant increase in risk of thyroid cancer following mantle radiation. Annual examination and palpation of the neck and thyroid gland are recommended for all survivors of Hodgkin's disease who were treated with mantle or chest radiation, regardless of the dose amount.3
1. Welker MJ, Orlov D. Thyroid nodules. Am Fam Physician. 2003;67:559–66.
2. SEER Program (National Cancer Institute [U.S.]). Cancer incidence and survival among children and adolescents: United States SEER Program, 1975–1995. Bethesda, Md.: National Cancer Insitute, 1999; NIH Publication No. 99-4649.
3. Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000;85:3227–32.
editor's note: This letter was sent to the authors of “Thyroid Nodules,” who declined to reply.
Send letters to email@example.com, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680. Include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the AAFP permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
This series is coordinated by Kenny Lin, MD, MPH, Associate Deputy Editor for AFP Online.
Copyright © 2003 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions